Predictors of incident tuberculosis among HIV-1-infected women in Tanzania

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 10, 2005, Pages 1105-1111

  Venkatesh, Pravina A ^a   Bosch, R J ^a   McIntosh, K ^a,b   Mugusi, F ^c   Msamanga, G ^c   Fawzi, W W ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

CD4; HIV; Malaria; Sub Saharan Africa; TB

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FETUS OUTCOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; PREDICTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TANZANIA; TUBERCULOSIS; VIREMIA; VITAMIN SUPPLEMENTATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ARM; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HIV-1; HUMANS; INCIDENCE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TANZANIA; TUBERCULOSIS; VIRAL LOAD; VITAMINS;

EID: 26444523388     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. UNAIDS. AIDS Epidemic Update, December 2004. Geneva, Switzerland: World Health Organization, UNAIDS, WHO 2004. www.unaids.org/wad2004/ EPIupdate2004_html_en/epi04_ 00_en.htm Accessed July 2005.
2. De Cock K M, Gnaore E, Adjorlolo G, et al. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. BMJ 1991; 302: 496-499.
3. Villarino M E, Dooley S W, Geiter L J, Castro K G, Snider D E Jr. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992; 41(RR-11): p 61.
4. Fatkenheuer G, Taelman H, Lepage P, et al. The return of tuberculosis. Diagn Microbiol Infect Dis 1999; 34: 139-146.
5. Badri M, Ehrlich R, Wood R, et al. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001; 5: 225-232.
6. De Cock K M, Soro I, Coulibaly M, Lucas S B. Tuberculosis and HIV infection in Sub-Saharan Africa. J Am Med Assoc 1992; 268: 1581-1587.
7. Whalen C C, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14: 1219-1228.
8. Wood R, Maartens G, Lombard C J. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23: 75-80.
9. Shor-Posner G, Miguez M J, Pineda L M, et al. Impact of selenium status on the pathogenesis of mycobacterial disease in HIV-1-infected drug users during the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 169-173.
10. Karyadi E, Schultink W, Nelwan R H, et al. Poor micronutrient status of active pulmonary tuberculosis patients in Indonesia. J Nutr 2000; 130: 2953-2958.
11. Glynn, J R, Warndorff D K, Malema S S, et al. Tuberculosis: associations with HIV and socioeconomic status in rural Malawi. Trans R Soc Trop Med Hyg 2000; 94: 500-503.
12. Kaplan J E, Hu D J, Holmes K K, et al. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996; 55: 1-11.
13. Garbus, Lisa. HIV/AIDS in Tanzania. UCSF AIDS Research Institute, AIDS Policy Research Center. Country AIDS Policy Analysis Project. July 2004. San Francisco, CA: Regents of the University of California, 2004. http://ari.ucsf.edu/policy/ profiles/Tanzania.pdf Accessed July 2005.
14. Fawzi W W, Msamanga G I, Spiegelman D, et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 1998; 351: 1477-1482.
15. World Health Organization. WHO International Collaborating Group for the Study of the WHO Staging System. Proposed World Health Organization staging system for HIV infection and disease: preliminary testing by an international collaborative cross-sectional study. AIDS 1993; 7: 711-718.
16. Mason M, Morris J S, Spate V L, et al. Comparison of whole blood, plasma and nails as monitors for the dietary intake of selenium. J Radioanal Nucl Chem 1998; 236: 29-34.
17. Department of Preventive Services, Ministry of Health. Manual of the National Tuberculosis and Leprosy Programme in Tanzania. 3rd ed. Dar es Salaam, Tanzania: Ministry of Health, 1995.
18. Grant A, Djomand G, Smets P, et al. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Cote d'Ivoire. AIDS ABSTRACTS, Barcelona, 1997; 11: 1357-1364.
19. Narain J P, Raviglione M C, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tubercle Lung Dis 1992; 73: 311-321.
20. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
21. Erratum in: Lancet 2002; 360: 1178.
22. Lawn S, Butera S, Folks T. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14: 753-777.
23. Goletti, D, Weissman D, Jackson R W, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157: 1271-1278.
24. Saadeh C. The erythrocyte sedimentation rate: old and new clinical applications. South Med J 1998; 91: 220-225.
25. Selwyn P, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
26. Crowle A J, May M H. Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Antimicrob Agents Chemother 1990; 34: 2217-2222.
27. Pisell T L, Hoffman I F, Jere C S, et al. Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection. AIDS 2002; 16: 1503-1509.
28. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997; 19: 913-923.
29. Marsh K, Greenwood B M. The immunopathology of malaria. Clin Trop Med Commun Dis 1986; 1: 91-125.
30. Chandra R K. Nutrition and the immune system: an introduction. Am J Clin Nutr 1997; 66: 460S-463S.
31. Harries A D, Nkhoma W A, Thompson P J, et al. Nutritional status in Malawian patients with pulmonary tuberculosis and response to chemotherapy. Eur J Clin Nutr 1988. 42: 445-450.
32. Niyongabo T, Henzel D, Ndayishimyie J M, et al. Nutritional status of adult inpatients in Bujumbura, Burundi (impact of HIV infection). Eur J Clin Nutr 1999; 53: 579-582.
33. Fawzi W W, Msamanga G I, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. New Engl J Med 2004; Jul1; 351: 23-32.
34. No authors listed. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. J Acquir Immune Defic Syndr 1991; 4: 970-975.
35. Hargreaves N J, Kadzakumanja O, Phiri S, et al. What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? Int J Tuberc Lung Dis 2001; 5: 113-122.